Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Brief Summary: To establish that at least 1 dose of daclatasvir combined with standard of care (pegylated interferon and ribavirin) is safe and well tolerated and demonstrates extended rapid virologic response rates at least 35% greater than those with placebo.


Options:
A: Arm Label: ABT-450/r/ABT-267 and ABT-333, Plus RBV; Type: EXPERIMENTAL; Interventions: Drug: ABT-450/r/ABT-267, ABT-333, Drug: Ribavirin | Arm Label: ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV; Type: EXPERIMENTAL; Interventions: Drug: ABT-450/r/ABT-267, ABT-333, Drug: Placebo for Ribavirin | Intervention Type: DRUG; Name: ABT-450/r/ABT-267, ABT-333; Assigned to Arm(s): ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV, ABT-450/r/ABT-267 and ABT-333, Plus RBV | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): ABT-450/r/ABT-267 and ABT-333, Plus RBV | Intervention Type: DRUG; Name: Placebo for Ribavirin; Assigned to Arm(s): ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV
B: Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Ribavirin, Drug: BI 201335, Drug: BI 207127 | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: BI 207127, Drug: BI 201335, Drug: Ribavirin | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: BI 207127, Drug: BI 201335, Drug: Ribavirin | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: BI 207127, Drug: Ribavirin, Drug: BI 201335 | Arm Label: 5; Type: EXPERIMENTAL; Interventions: Drug: BI 201335, Drug: BI 207127, Drug: Ribavirin | Arm Label: 6; Type: EXPERIMENTAL; Interventions: Drug: Ribavirin, Drug: BI 201335, Drug: BI 207217 | Arm Label: 7; Type: EXPERIMENTAL; Interventions: Drug: BI 207127, Drug: BI 201335 | Arm Label: 8; Type: EXPERIMENTAL; Interventions: Drug: BI 207127, Drug: Ribavirin, Drug: BI 201335 | Arm Label: 9; Type: EXPERIMENTAL; Interventions: Drug: BI 207127, Drug: BI 201335, Drug: Ribavirin | Arm Label: 10; Type: EXPERIMENTAL; Interventions: Drug: BI 201335, Drug: BI 207127, Drug: Ribavirin | Arm Label: 11; Type: EXPERIMENTAL; Interventions: Drug: Ribavirin, Drug: BI 207127, Drug: BI 201335 | Arm Label: 12; Type: EXPERIMENTAL; Interventions: Drug: Ribavirin, Drug: BI 201335, Drug: BI 207127 | Intervention Type: DRUG; Name: BI 207127; Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): 5 | Intervention Type: DRUG; Name: BI 207127; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): 11 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): 6 | Intervention Type: DRUG; Name: BI 207127; Assigned to Arm(s): 5 | Intervention Type: DRUG; Name: BI 207127; Assigned to Arm(s): 9 | Intervention Type: DRUG; Name: BI 207127; Assigned to Arm(s): 11 | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): 10 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): 5 | Intervention Type: DRUG; Name: BI 207127; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: BI 207127; Assigned to Arm(s): 7 | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): 6 | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): 11 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): 12 | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): 12 | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): 7 | Intervention Type: DRUG; Name: BI 207127; Assigned to Arm(s): 12 | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): 9 | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: BI 207127; Assigned to Arm(s): 8 | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): 8 | Intervention Type: DRUG; Name: BI 207217; Assigned to Arm(s): 6 | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): 8 | Intervention Type: DRUG; Name: BI 207127; Assigned to Arm(s): 10 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: BI 207127; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): 9 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): 10
C: Arm Label: Daclatasvir plus peg-interferon alfa-2a and ribavirin (20 mg); Type: EXPERIMENTAL; Interventions: Drug: Daclatasvir, Drug: peg-interferon alfa-2a, Drug: ribavirin | Arm Label: Daclatasvir plus peg-interferon alfa-2a and ribavirin (60 mg); Type: EXPERIMENTAL; Interventions: Drug: Daclatasvir, Drug: peg-interferon alfa-2a, Drug: ribavirin | Arm Label: Placebo plus peg-interferon alfa-2a and ribavirin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: peg-interferon alfa-2a, Drug: ribavirin | Intervention Type: DRUG; Name: Daclatasvir; Assigned to Arm(s): Daclatasvir plus peg-interferon alfa-2a and ribavirin (20 mg) | Intervention Type: DRUG; Name: Daclatasvir; Assigned to Arm(s): Daclatasvir plus peg-interferon alfa-2a and ribavirin (60 mg) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo plus peg-interferon alfa-2a and ribavirin | Intervention Type: DRUG; Name: peg-interferon alfa-2a; Assigned to Arm(s): Daclatasvir plus peg-interferon alfa-2a and ribavirin (20 mg), Daclatasvir plus peg-interferon alfa-2a and ribavirin (60 mg), Placebo plus peg-interferon alfa-2a and ribavirin | Intervention Type: DRUG; Name: ribavirin; Assigned to Arm(s): Daclatasvir plus peg-interferon alfa-2a and ribavirin (20 mg), Daclatasvir plus peg-interferon alfa-2a and ribavirin (60 mg), Placebo plus peg-interferon alfa-2a and ribavirin
D: Arm Label: Genotype 2 treatment-naive; Type: EXPERIMENTAL; Interventions: Drug: Sofosbuvir, Drug: RBV | Arm Label: Genotype 2/3 treatment-experienced; Type: EXPERIMENTAL; Interventions: Drug: Sofosbuvir, Drug: RBV | Arm Label: Genotype 1/3/4 treatment-naive; Type: EXPERIMENTAL; Interventions: Drug: Sofosbuvir, Drug: RBV | Intervention Type: DRUG; Name: Sofosbuvir; Assigned to Arm(s): Genotype 1/3/4 treatment-naive, Genotype 2 treatment-naive, Genotype 2/3 treatment-experienced | Intervention Type: DRUG; Name: RBV; Assigned to Arm(s): Genotype 1/3/4 treatment-naive, Genotype 2 treatment-naive, Genotype 2/3 treatment-experienced

Answer: C